Medicenna Therapeutics Announces Participation in Upcoming Conferences
TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as
(Financial Post, 2025-10-20T11:03:53Z)